Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have earned a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.71.

A number of equities research analysts have commented on the stock. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 target price for the company. Oppenheimer dropped their target price on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th.

Perspective Therapeutics Stock Up 1.1 %

Shares of CATX opened at $13.25 on Friday. The firm’s 50 day moving average price is $13.82. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. On average, sell-side analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CATX. RIA Advisory Group LLC raised its position in shares of Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after buying an additional 99,293 shares during the last quarter. Bleakley Financial Group LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at about $40,000. Vanguard Group Inc. grew its position in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after purchasing an additional 4,566,356 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in shares of Perspective Therapeutics in the first quarter worth about $6,069,000. Finally, Janus Henderson Group PLC bought a new position in Perspective Therapeutics during the first quarter valued at approximately $15,511,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.